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Introduction: Injecting human glioma-initiating cells into brain of immunodeficient rodents is a recently introduced model for studying properties of 
human gliomas. Fresh human glioma cells implanted into immunodeficient rats produced slowly growing, invasive tumors with little 
neovascularization, whereas serial passaging of these cells in animals led to rapidly growing, less differentiated and vascularized tumors (1). Proton 
spectra of gliomas at lower magnetic fields show only few resolved spectral lines, thus limiting the number of metabolites to be quantified. In this 
study, separated human glioma-initiating fresh cells (FC) and cultured cells (CC) (2) were injected into the brain of nude mice. The aim was to study 
the effect of tumor development on the metabolism of brain tissue in the injected site and to measure the metabolic profiles of the gliomas formed 
from FC and CC at 14.1 T. 
Methods: Human glioma-initiating cells were injected into the 
striatum of ten nude mice. Five mice having injected FC were 
examined 3-4.5 months after the injection, another five animals 
injected with CC were measured before and on days 7, 14, 21, 28, 
35 and 42 after the cell injection on a 14.1 T/26 cm Varian animal 
scanner. A two-loop quadrature coil with dimensions of 21 mm × 
14 mm was used as a transceiver. The protocol consists of T2-
weighted axial imaging followed by short echo-time (TR/TE = 
4000/2.8 ms) SPECIAL (3) proton MR spectroscopy from a VOI 
~ 10 μL located inside a tumor or, before detecting solid tumor, at 
the injection site and symmetrically in the contralateral 
hemisphere. Finally, a series of T1-weighted images were 
measured after intraperitoneal administration of Gd(DTPA). 
Results: Tumors grown from CC appeared in the injection sites 
on both T2- and post-contrast T1-weighted MR images on days 
28 or 35 and showed necrosis and Gd enhancement. The gliomas 
from FC appeared after about 3 months and showed no necrosis 
and very little Gd enhancement. Interestingly, before detecting 
solid tumors from CC (days 7 to 21) the spectra from the 
hemisphere injected with CC showed a gradual, about 15 % 
decrease in concentration of NAA+NAAG and glutamate (Glu), a 
40 % decrease in glucose (Glc), a 30 % increase in glycine (Gly) 
but no change in choline (PCho+GPC) (Fig. 1). Well resolved 
spectra of solid tumors were obtained (Fig. 2) and metabolite 
concentrations of 17 metabolites 
were determined. The spectra of 
solid tumors grown from CC (Fig. 2c) 
showed dramatic changes of many 
metabolites compared to the 
contralateral hemisphere including 
intense peaks of lipids, a 3- to 5-fold 
decrease in  NAA+NAAG, Cr+PCr, 
Gln+Glu, GABA and taurine (Tau) 
and a 2- to 5-fold increase in 
PCho+GPC, Gly, alanine (Ala) and 
lactate (Lac). The metabolic profile  
of the tumors grown from FC (Fig. 
2b) was slightly different, with myo-inositol (Ins) about 100 %  higher and PCho+GPC about 50 % higher than in the tumors grown from CC. In 
addition, the concentrations of Cr+PCr, Lac and Ala in the tumors from FC were almost the same as in the normal tissue and no lipid peaks were 
detected. 
Discussion and Conclusions: Our experiments demonstrate that changes in concentrations of a number of metabolites can be detected in brain tissue 
prior to overt tumor formation. The changes in metabolite concentrations at the injection site of CC are in an excellent agreement with metabolic 
changes observed in tumor surroundings in patients (4). Thus, nude-mice model seems to be suitable for studying tumor infiltration, which is 
important in therapy management and surgical planning. The different metabolic profiles of tumors formed from FC and CC agree well with spectral 
features of lower- and higher-grade gliomas, respectively, observed in humans (5). In conclusion, high-field MR spectroscopy is capable of detecting 
early stages of a malignant process in brain and could be useful in distinguishing between various grades of gliomas.  
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Fig. 2. Proton spectra of mouse brain from the contralateral side (a),  from tumors grown from FC (b) and from CC (c) 
Fig. 1. Absolute concentrations of metabolites in the injected and 
contralateral hemispheres at various time points before appearing solid 
tumors. The marked concentrations were significantly different. 
